UNGASS 2016 and beyond: Seizing the opportunity to improve drug policy
Past Event
Vanda Felbab-Brown explains UNGASS 2016
Vanda Felbab-Brown explains UNGASS 2016
UNGASS 2016 and beyond: Seizing the opportunity to improve drug policy
As the world prepares for the April 2016 Special Session of the United Nations General Assembly on the World Drug Problem (UNGASS 2016), there is an emerging “dissensus” among states on how best to address the costs, harms, and risks associated with illicit drugs. An increasing number of countries in the Americas and Europe are now opposed to punitive counterdrug policies and are experimenting with reform, even as major powers such as Russia and China continue to defend a prohibitionist interpretation of the international counternarcotics regime. And the United States, once the global regime’s chief enforcer, is now itself a hotbed of experimentation as nearly half of its states have implemented medicinal or legalized access to cannabis.
On April 7, the Brookings Foreign Policy and Governance Studies programs hosted a conversation on what we can learn from drug policy reforms now being conducted in the United States and across the globe and what flexibility will exist in the global counternarcotics regime for implementing improved drug policies after UNGASS 2016.
For more on this topic, check out:
Brookings Project on Improving Global Drug Policy
The new Brookings Essay “The medical marijuana mess: a prescription for fixing a broken policy” by John Hudak
Agenda
UNGASS 2016 and beyond: Seizing the opportunity to improve drug policy
On April 7, the Brookings Foreign Policy and Governance Studies programs hosted a conversation on what we can learn from drug policy reforms now being conducted in the United States and across the globe and what flexibility will exist in the global counternarcotics regime for implementing improved drug policies after UNGASS 2016.
Harold Trinkunas
Nonresident Senior Fellow - Foreign Policy, Latin America Initiative
Deputy Director, Center for International Security and Cooperation, Freeman Spogli Institute, Stanford University
John Hudak
Deputy Director - Center for Effective Public Management
Senior Fellow - Governance Studies
John Walsh
Director for Drug Policy and the Andes - Washington Office on Latin America
More Information
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.
More
The Duque government’s drug policy in Colombia is taking on a progressively ominous and counterproductive direction. It threatens to undermine the incomplete and struggling peace process, misdirect law enforcement resources, augment the alienation of coca farmers from the state and undermine human rights and drug users’ access to health services in Colombia. With their emphasis on criminalization of even drug possession for personal use and forced eradication, the announced policies clearly cater to the Trump administration’s doctrinaire and discredited drug policy preferences that harken back to the 1980s. But without sustainable livelihoods already in place, forced eradication will not sustainably reduce coca cultivation and cocaine production. The dominance of zero-coca thinking in Colombia whereby a community has to eradicate all coca first before it starts receiving even meager assistance from the state never produced positive results in Colombia.
Uruguay’s cannabis law: Pioneering a new paradigm
